Companies / OIL

OPTISCAN IMAGING LIMITED

ASX:OILHealth Care Equipment & Services
1.04B shares on issueASX (delayed) · as of 28 July 2026$0.15price · delayed$167.1Mmarket cap · indicative
B
Dilution grade

Runway 4–8 quarters; 1 cash raise in 24 months; 0% of shares in the money

Cash runway5.5 quarters of funding
Share-count growth (24m)0.0%no issuance filings since 2024
Raise cadence (24m)1 cash raise
Options & rights overhang0.9% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

OPTISCAN IMAGING LIMITED's ordinary share count stood at 1.04B between September 2025 and that reporting date, with one observation available. The company has not lodged any new Appendix 2A share-issuance filings since January 2024. It raised capital once in the 24-month window for total proceeds of A$17.8M, most recently in August 2025 for A$17.8M. Options and rights could convert into 9M new shares, equal to 0.9% of the current share count, with 0% in the money and the nearest expiry in June 2027. At the March 2026 quarter the company reported A$13.5M in cash, covering 5.5 quarters. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
0.9%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
5.5 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 1.04B per ASX (delayed) (28 July 2026).
0.88B0.94B1.00BDec 24Sept 25July 26Cash raise · 26 Aug 2025

Cash runway

5.5 qtrs
More than four quarters of funding at the recent spend rate.
$13.5M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
15 Jan 20263G · unquotedOIL : ORDINARY FULLY PAID1.04BAppendix 3G
23 Sept 20252A · quoted issueOIL : ORDINARY FULLY PAID1.04BAppendix 2A
29 May 20253H · cancellationOIL : ORDINARY FULLY PAID835.3MAppendix 3H
10 Mar 20253H · cancellationOIL : ORDINARY FULLY PAID835.3MAppendix 3H
12 July 20243G · unquotedOIL : ORDINARY FULLY PAID835.3MAppendix 3G
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

1 cash raise in the last 24 months · 1 in the last 12 months

$17.8M
Capital raise
26 Aug 2025
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

0.9%
Total overhang · of current shares
0.0%
In the money · at current price
9.2M
Potential new shares
June 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
22 May 2026Mr Ron SongSell3.0M—$360k3Y notice
13 Jan 2026Mr Robert CookeOther———3Y notice
13 Jan 2026Ms Karen BorgOther335k——3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

21 July 2026$POptiscan Signs New Research Agreement for Breast Study
20 July 2026$PHead and Neck Study Progressing Ahead of Schedule
6 July 2026$POptiscan Launches InSpecta Device for Veterinary Medicine
3 June 2026$PHalfway Mark Reached in Optiscan Breast Cancer Study
1 June 2026$PSecond Anniversary of Optiscan and Mayo Clinic Agreement
25 May 2026Change of Director's Interest Notice
19 May 2026$POptiscan Receives $1.69m R&D Tax Refund
29 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
30 Mar 2026$POptiscan Submits InSpecta FDA Dossier
17 Mar 2026Change in substantial holding
24 Feb 2026Half Year Report - 31 December 2025
24 Feb 2026$PAppendix 4D
29 Jan 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
15 Jan 2026Change of Director's Interest Notice x4
15 Jan 2026Notification regarding unquoted securities - OIL
29 Dec 2025Change of Director's Interest Notice
4 Dec 2025Investor Presentation
2 Dec 2025$POptiscan Initiates Head & Neck Cancer Imaging Study
1 Dec 2025OIL Investor Webinar Invite
14 Nov 2025OIL Results of Annual General Meeting

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.